Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31412435 | 1.00 | CFTR (0.33) | CFTRGRM2GRM3KCNH2CYP3A4 | |
| SCHEMBL23905581 | 1.00 | CFTR (0.33) | CFTRGRM2GRM3KCNH2CYP3A4 | |
| SCHEMBL23904871 | 0.93 | CFTR (0.33) | CFTRKCNH2CYP3A4TRPV1PTGS2 | |
| SCHEMBL23905374 | 0.90 | CFTR (0.33) | CFTRGRM2GRM3KCNH2CYP3A4 | |
| SCHEMBL23905533 | 0.90 | CFTR (0.33) | CFTRGRM2GRM3KCNH2CYP3A4 | |
| SCHEMBL24984837 | 0.89 | CFTR (0.33) | CFTRGRM2KCNH2CYP3A4TRPV1 | |
| SCHEMBL23196089 | 0.89 | CFTR (0.33) | CFTRGRM2KCNH2CYP3A4TRPV1 | |
| SCHEMBL24988016 | 0.89 | CFTR (0.33) | CFTRKCNH2CYP3A4TRPV1 | |
| SCHEMBL31412378 | 0.89 | CFTR (0.33) | CFTRKCNH2CYP3A4TRPV1 | |
| SCHEMBL24984667 | 0.88 | TRPV1 (0.35) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-11572367-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2021198981-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | Janssen Biopharma, Inc. (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | CFTR 283/4885GRM2 4163/4885GRM3 2358/4885 |
| US-11572367-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | CFTR 283/4885GRM2 4163/4885GRM3 2358/4885 |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | CFTR 283/4885GRM2 4163/4885GRM3 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.